Sanofi and Regeneron Report Results of Dupixent (dupilumab) in Part A of P-lll Study for Eosinophilic Esophagitis (EoE)

 Sanofi and Regeneron Report Results of Dupixent (dupilumab) in Part A of P-lll Study for Eosinophilic Esophagitis (EoE)

Sanofi and Regeneron Report Results of Dupixent (dupilumab) in Part A of P-lll Study for Eosinophilic Esophagitis (EoE)

Shots:

  • Part A of P-lll study involves assessing of Dupixent (qw, 300mg) vs PBO in 81 patients aged≥ 12 yrs. with EoE. The study resulted in meeting its co-primary and all key 2EPs, presented at the virtual ACG 2020 and UEG Week 2020
  • Results: Patients reported significant improvement on DSQ as 4 wks. and continued to improve through 24 wks; reduced EEC (<15) eos/hpf (64% vs 8%) @24wks. Peak EEC (71% vs 3%). ET changes associated with the disease reduced (0.761 and 0.753 vs 0.001 and 0.012) reduction @24wks.; gene expression patterns associated with type 2 inflammation and EoE were reduced (1.97-fold & 2.66-fold vs 0.32-fold & 0.16-fold); SAEs (86% vs 82%)
  • Dupixent is mAb inhibiting the signaling of the IL-4 and IL-13 proteins and has received the US FDA’s BT designation for the treatment of patients ≥12yrs. with EoE

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Chemistry World

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post